NanoPhoria Bioscience Secures €83.5 Million Series A To Heart Failure Therapy And Expand Portfolio For Novel Nano-In-Micro Delivery Platform

The investment, supporting its lung-to-heart drug delivery platform, was led by XGEN Venture, Sofinnova Partners, and CDP Venture Capital, with participation from Panakes Partners and another undisclosed investor.

“This financing is a transformational milestone for NanoPhoria,” said Claudio De Luca, CEO and Co-founder. “It enables us to accelerate clinical development of NP-MP1 and expand our pipeline. Our innovative delivery platform allows us to target previously inaccessible cellular targets in the cardiomyocyte, thereby bringing us closer to delivering life-changing treatments for patients living with serious cardiac and other chronic conditions who are underserved by existing treatments.”

“We are profoundly grateful to our scientific founders, our investors, our Board, and our Chair, Suman Shirodkar, whose vision and efforts have shaped NanoPhoria’s progress and ambition,”

NanoPhoria’s Series A marks one of Europe’s largest 2025 biotech financings in cardiovascular innovation. While investments in cardiac diagnostics and therapies have been growing, few early-stage rounds have matched this scale.

Recent examples include Ultromics (€48M, UK) for AI-driven cardiology diagnostics, DESKi (€5.2M, France) for cardiac imaging, and Maxion Therapeutics (€68M, UK) for its “knotbody” drug platform. Others, like Ciloa (€6.5M) and SeaBeLife (€2M), highlight sustained investor interest in life sciences.

NanoPhoria stands out as a Italy-based biotech leading cardiovascular drug delivery innovation, reflecting strong investor confidence in targeted therapies and next-gen heart treatments.

“NanoPhoria’s platform has the potential to redefine treatment paradigms in cardiovascular and other chronic diseases which is why we are excited to invest in this company,” added Henrijette Richter, Managing Partner at Sofinnova Partners. “This financing builds on the early support of my colleague Lucia Faccio, Partner in the Sofinnova Telethon Strategy, whose role was instrumental in supporting the company in its early days to take shape. The investment reflects Sofinnova’s broader commitment to backing world-class science across Europe, from early-stage company creation to late-stage growth.”

Founded in 2022, NanoPhoria is a preclinical-stage biotech company developing inhalable cardiovascular therapies using non-viral nano-delivery of biologics. Its proprietary platform enables tissue-targeted delivery of therapeutic peptides and RNAs through biomimetic calcium-phosphate nanoparticles, designed for inhalation or other administration routes.

The new funding will advance NanoPhoria’s lead candidate, NP-MP1, through IND-enabling and early clinical studies. NP-MP1, a first-in-class peptide targeting cardiac L-type calcium channels, aims to improve ejection fraction in heart failure patients (HFrEF). Delivered via NanoPhoria’s lung-to-heart nano-in-micro technology, NP-MP1 has shown strong preclinical efficacy, addressing the root cause of HFrEF a disease affecting millions worldwide with a five-year mortality rate near 40%.

“This investment perfectly aligns with XGEN’s strategy to lead early financing rounds in the most innovative Italian startups that address true medical needs,” said Paolo Fundarò, Managing Partner at XGEN Venture. “NanoPhoria’s science provides a novel, and viable, way of delivering highly potent therapeutics directly to the heart and we look forward to working alongside such a fantastic syndicate of investors.”